Argenx | Sustainability Performance
This company focuses on developing innovative therapies for severe autoimmune diseases and cancers. Its research emphasizes human monoclonal antibodies to target underlying pathological mechanisms.
2008
Netherlands
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#587
Overallⓘ#13
in Netherlandsⓘ#8
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsDigital emissionsEnergy consumptionWaste ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Leading
Critical
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
113.5
B/M 128.6
0.0
B/M 0.0
Powered by illuminem and GIST Impact
Controversy level
- argenx SE has faced multiple US patent infringement disputes including the 2024 Momenta Pharmaceuticals/Johnson & Johnson lawsuits over Vyvgart (efgartigimod) IP, plus sustained scrutiny over US Medicare Part B pricing for the autoimmune drug affecting US payer relationships and access.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.